

Highly Enantioselective Arylation of *N*-Tosylalkylaldimines Catalyzed by Rhodium-Diene Complexes

Zhe Cui,^{†,‡} Hong-Jie Yu,[†] Rui-Feng Yang,[†] Wen-Yun Gao,[‡] Chen-Guo Feng,^{*,†} and Guo-Qiang Lin^{*,†}

[†]Key Laboratory of Synthetic Chemistry of Natural Substances, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, Shanghai 200032, P.R. China

[‡]College of Life Sciences, Northwest University, Xi'an, Shaanxi 710069, P.R. China

Supporting Information

ABSTRACT: A highly enantioselective rhodium-catalyzed arylation of aliphatic *N*-tosylaldimines has been developed. The combination of chiral bicyclo[3.3.0]octadiene ligands, an active rhodium hydroxide complex, and neutral reaction conditions is the key to achieving high yield and enantioselectivity. The application of this method is demonstrated by the enantioselective synthesis of chiral 2-aryl pyrrolidines and piperidines in a one-pot procedure. Furthermore, excellent results are also obtained for the imine substrates with the more readily cleavable *N*-nosyl protecting group.

Thiral α -arylamines are a common structural motif in natural products as well as in pharmaceutical molecules. Some examples are the naturally occurring cytokine modulator (-)-cytoxazone,¹ the third-generation antihistamine levocetirizine,² and the selective Kv1.5 blocker BMS-394136.³ Among the methods to synthesize these structures, asymmetric rhodium-catalyzed arylation of imines represents an attractive approach. Since the first example reported by Tomioka in 2004,4 significant efforts have been devoted to this rhodium-catalyzed transformation by various research groups. 5-8 In spite of the considerable advancements, the imine substrates are usually limited to aromatic imines. The major challenge in the addition of aliphatic imines is their tendency to undergo imine-enamine tautomerization, decomposition, and self-condensation under common reaction conditions. The only example with aliphatic imines was reported by Ellman and co-workers in 2008, utilizing a chiral bisphosphine ligand.⁹ The resulting chiral α -aryl alkylamines were prepared in 68-96% yield with 81-98% ee. Therefore, a more efficient catalytic system is still highly desirable for the preparation of these interesting substructures in higher yield and with improved enantioselectivity.

In 2004, Hayashi reported a rhodium-catalyzed arylation of *N*-tosylarylaldimines with chiral bicyclo[2.2.2]octadiene ligands.^{8a} Since then, a wide variety of chiral diene ligands have been successfully applied in this transformation.^{7,8} Compared with chiral phosphine ligands, chiral diene ligands have provided higher enantioselectivity in many cases, especially the chiral bicyclo-[3.3.0]octadiene ligands, which were first introduced by our group in 2007.^{7a} They can readily be prepared in both enantiomeric forms and were found to be superior ligands for enantioselective arylation of *N*-tosyl- or *N*-nosylarylaldimines, providing chiral diaryl amines in extremely high enantioselectivity (98–99% ee). Herein, we report our recent success in the highly

efficient arylation of N-tosylalkylaldimines with chiral bicyclo-[3.3.0]octadiene ligands.¹⁰

Our investigation commenced with the use of *N*-tosylimine 1a as a model substrate.¹¹ Under the standard reaction conditions previously developed for *N*-tosylarylimines, the addition of phenylboronic acid to 1a, with bicyclo[3.3.0] octadienes 4a-4d as ligands for screening, gave the desired product 3aa in excellent enantioselectivities (98–99% ee). However, the yields were unsatisfactory (22–40%; Table 1, entries 1–4). Attempts to improve the reaction yield by employing KHF₂ as an additive^{7c} (entry 5) or Ellman's reaction conditions proved to be fruitless (entry 6).⁹

We postulated that the low yields were due to the rapid decomposition of *N*-tosylimine **1a**. To verify this speculation, several control experiments were performed. It was found that \sim 75% of imine **1a** was destroyed in hot aqueous dioxane (70 °C) in 3.5 h. This process was accelerated in the presence of a given base. For example, no imine **1a** was observed after 3.5 h when K₃PO₄ was added. According to this stability information, there are two possible options to improve the reaction yield: (1) use a more active catalyst to accelerate the imine transforming process or (2) use a base/acid-free reaction condition to slow the decomposition process.

In the following optimization studies, the reaction was carried out with $[RhCl(4a)]_2$ as catalyst without any base additive. Though only 29% yield was obtained, the result was promising, as this arylation could occur under a neutral condition (Table 2, entry 1). When more active $[Rh(OH)(4a)]_2$ was tested,¹² the desired adduct was obtained in almost quantitative yield (99%) with excellent enantioselectivity (>99% ee, entry 2). High enantioselectivities and slightly lower yields were observed when the reactions were conducted at lower temperatures (entries 3 and 4). Dropping the catalyst to 1 mol % did not affect the high selectivity (entry 5). The presence of 4 Å MS was also helpful for achieving high reaction yield (entry 6).

With the optimal reaction conditions in hand (Table 2, entry 2), the reaction scope was examined. Varying the substituent at the 4- or 3-position of the phenyl ring of the boronic acid with either an electron-donating or -withdrawing group gave the product in high yields (91-99%) with excellent enantioselectivities (98 to >99% ee; Table 3, entries 1-7). Slight decreases in the reaction selectivity were observed when the more sterically hindered 2-methoxyphenylboronic acid and 1-napthylboronic acid were used (entries 8 and 9). However, the enantioselectivity could be

 Received:
 May 23, 2011

 Published:
 July 19, 2011



 Table 1. Ligand Screening and Initial Optimization of Re

 action Conditions^a

[RhCl(CoHa)a]a/4

	N ^{_Ts}	+ PhB(OH) ₂ (2 equiv)	(3 mol% Rh)		HŅ ^{∠TS}	
Me	√Чн		additive, toluen	e Me	Me	
1a		2a		;	3aa	
entry	ligand	temp (°C)	additive (equiv)	yield ^b (%)	ee ^c (%)	
1	4a	55	Et ₃ N (2.0)	28	99	
2	4b	55	$Et_{3}N(2.0)$	22	99	
3	4c	55	$Et_{3}N(2.0)$	33	98	
4	4d	55	$Et_{3}N(2.0)$	43	98	
5^d	4a	55	$KHF_{2}(4.0)$	56	75	
6 ^e	4a	70	$K_{3}PO_{4}(0.2)$	51	99	



^{*a*} The reaction was carried out with **1a** (0.25 mmol), phenylboronic acid (0.5 mmol), $[RhCl(C_2H_4)_2]_2$ (0.0038 mmol), and **4** (0.0085 mmol) in toluene (2 mL) at 55 °C, unless otherwise noted. ^{*b*} Isolated yield. ^{*c*} Determined by chiral HPLC analysis. ^{*d*} 4.0 M aqueous KHF₂. ^{*e*} Dioxane was used as solvent instead of toluene, and 4 Å MS (300 mg) was added.

Table 2. Further Optimization Studies^a



^{*a*} The reaction was carried out with 1a (0.25 mmol), phenylboronic acid (0.5 mmol), 4 Å MS (300 mg), and rhodium catalyst (0.0038 mmol) in dioxane (2 mL) at 70 °C, unless otherwise noted. ^{*b*} Isolated yield. ^{*c*} Determined by chiral HPLC analysis. ^{*d*} 1 mol % catalyst loading. ^{*e*} Without 4 Å MS.

improved by using $[Rh(OH)(4d)]_2$ as catalyst, in which the hindered phenyl group in the diene ligand was replaced by a flexible benzyl group. A variety of *N*-tosyl alkylaldimines with carbon chains differing in length and branched structure turned to be suitable substrates, providing the corresponding products in high yields (92–95%) and excellent enantioselectivities (>99% ee, entries 10–15). Imines with terminal functional groups such as

Table 3. Asymmetric Rhodium-Catalyzed Arylation of AliphaticN-Tosylimines^a

N ^{Ts} H 1	+ ArB(OH) ₂ (2 equiv) 2	ArB(OH) ₂	[Rh(OH)(4a)] ₂ (3 mol% Rh)	HN Ts
		(2 equiv) 2	dioxane, 4Å MS 70 °C	R Ar

entry	R	Ar	3	yield ^{b} (%)	$ee^{c,d}$ (%)
1	Et (1a)	$C_{6}H_{5}\left(2a\right)$	3aa	99	>99
2	Et (1a)	$4\text{-}MeOC_{6}H_{4}\left(\mathbf{2b}\right)$	3ab	99	>99
3	Et (1a)	$4-MeC_{6}H_{4}(2c)$	3ac	99	99
4	Et (1a)	$4-CF_{3}C_{6}H_{4}(2d)$	3ad	93	99
5	Et (1a)	$\text{4-ClC}_{6}\text{H}_{4}\left(2e\right)$	3ae	99	98
6	Et (1a)	$3-MeC_{6}H_{4}(2f)$	3af	92	99
7	Et (1a)	$3\text{-}MeOC_{6}H_{4}\left(2g\right)$	3ag	98	99
8^e	Et (1a)	1-naphthyl $(2h)$	3ah	99 (97)	91 (93)
9 ^e	Et (1a)	$2\text{-}MeOC_{6}H_{4}\left(2i\right)$	3ai	91 (96)	93 (98)
10	<i>n</i> -Pr (1b)	$C_6H_5(2a)$	3ba	92	>99
11	<i>i</i> -Pr (1c)	$C_{6}H_{5}\left(2a\right)$	3ca	94	>99
12	<i>n</i> -Bu(1d)	$C_6H_5\left(2a\right)$	3da	95	>99
13	<i>i</i> -Bu (1e)	$C_6H_5(2a)$	3ea	92	>99
14	c-Hex (1f)	$C_6H_5(2a)$	3fa	93	>99
15	$Et_2CH(1g)$	$C_6H_5\left(2a\right)$	3ga	95	>99
16	$PhCH_2CH_2$ (1h)	$C_{6}H_{5}\left(2a\right)$	3ha	99	>99
17	$BnOCH_{2}CH_{2}CH_{2}\left(1i\right)$	$C_{6}H_{5}\left(2a\right)$	3ia	90	>99
18	$ClCH_{2}CH_{2}CH_{2}\left(1j\right)$	$C_{6}H_{5}\left(2a\right)$	3ja	87	>99
19	$ClCH_{2}(CH_{2})_{2}CH_{2}(1k)$	$C_6H_5(2a)$	3ka	89	>99

^{*a*} All reactions were performed as described in Table 2 (entry 2) on a 0.25 mmol scale, unless otherwise noted. ^{*b*} Isolated yield. ^{*c*} Determined by chiral HPLC analysis. ^{*d*} The absolute configurations of **3aa** and **3ca** were determined to be *R* by comparison with the known optical rotations $[\alpha]_D$ in the literature. The absolute configurations of other compounds were also assigned as *R* by consideration of the stereochemical pathway. ^{*e*} The data in parentheses are results obtained with $[Rh(OH)(4d)]_2$ as catalyst.

Ph, BnO, or Cl were also acceptable substrates, affording the desired adducts in 87–99% yield and >99% ee (entries 16–19). This methodology could potentially be used for the synthesis of other interesting nitrogen-containing compounds, such as cyclic amines.

The application of this strategy was next demonstrated by the preparation of chiral 2-aryl pyrrolidines and piperidines. Owing to their wide presence in biologically active compounds, great efforts have been pursued for their asymmetric synthesis.^{13,14} Thus, *N*-tosylimines **1***j* and **1***k* were reacted with representative arylboronic acids, followed by treatment with base in a one-pot procedure, affording several 2-aryl pyrrolidines and piperidines **5** in high yields (73–84%) and excellent enantioselectivities (\geq 99% ee; Table 4). The tosyl group in each resulting product was removed by reduction with naphthalene/Li. For example, compound **5c** was converted to the chiral amine **6**, an enantiomer of the key unit for BMS-394136, in 77% yield (Scheme 1).³

Currently, we are also studying the addition to imines with more readily cleavable protecting groups. Some preliminary results for the *N*-nosylimine substrates are shown in Table 5.¹⁵ Although the reaction yields were slightly decreased compared with those

Table 4. One-Pot Synthesis of Chiral 2-Aryl Pyrrolidine and Piperidine Derivatives



^{*a*} All addition reactions were performed as described in Table 2 (entry 2) and followed by a base-promoted cyclization sequence in a one-pot procedure (See Supporting Information for details).

Scheme 1. Removal of Tosyl Protecting Group







^{*a*} All addition reactions were performed as described in Table 2 (entry 2).

obtained with N-tosylimines, excellent enantioselectivities were maintained.

In summary, we have developed a rhodium-catalyzed asymmetric addition of arylboronic acids to aliphatic *N*-tosylimines using chiral rhodium-diene complexes as catalyst.¹⁶ The bicyclo-[3.3.0] octadienes proved to be superior ligands for this transformation, providing the resulting products in exceptionally high enantioselectivity (typically \geq 99% ee). The combination of an active rhodium hydroxide catalyst and neutral reaction conditions is the key to obtaining high reaction yields. This method was applied to the enantioselective synthesis of chiral 2-aryl pyrrolidines and piperidines in a one-pot procedure. Extension of this methodology to aliphatic *N*-nosylimines is also very successful.

ASSOCIATED CONTENT

Supporting Information. Experimental procedures and characterization data, ¹H and ¹³C NMR spectra, and HPLC profiles. This material is available free of charge via the Internet at http://pubs.acs.org.

AUTHOR INFORMATION

Corresponding Author

fengcg@sioc.ac.cn; lingq@mail.sioc.ac.cn

ACKNOWLEDGMENT

Financial support from the Major State Basic Research Development Program (2010CB833302), the National Natural Science Foundation of China (21002112), and the State Key Laboratory of Bio-organic and Natural Products Chemistry (Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences) is acknowledged. We acknowledge Dr. Han-Qing Dong for help in the preparation of this manuscript.

REFERENCES

 (a) Kakeya, H.; Morishita, M.; Kobinata, K.; Osono, M.; Ishizuka, M.; Osada, H. J. Antibiot. 1998, 51, 1126. (b) Kakeya, H.; Morishita, M.; Koshino, H.; Morita, T.; Kobayashi, K.; Osada, H. J. Org. Chem. 1999, 64, 1052.

(2) (a) Grant, J. A.; Riethuisen, J.-M.; Moulaert, B.; DeVos, C. Ann. Allergy Asthma Immunol. 2002, 88, 190. (b) Day, J. H.; Ellis, A. K.; Rafeiro, E. Drugs Today 2004, 40, 415. (c) Walsh, G. M. Curr. Med. Chem. 2006, 13, 2711.

(3) Lloyd, J.; Finlay, H. J.; Vacarro, W.; Hyunh, T.; Kover, A.; Bhandaru, R.; Yan, L.; Atwal, K.; Conder, M. L.; Jenkins-West, T.; Shi, H.; Huang, C.; Li, D.; Sun, H.; Levesque, P. *Bioorg. Med. Chem. Lett.* **2010**, *20*, 1436.

(4) Kuriyama, M.; Soeta, T.; Hao, X.; Chen, Q.; Tomioka, K. J. Am. Chem. Soc. 2004, 126, 8128.

(5) For review, see: Marques, C. S.; Burke, A. J. *ChemCatChem* 2011, 3, 635.

(6) For examples with chiral ligands based on phosphorus coordination, see: (a) Duan, H.-F.; Jia, Y.-X.; Wang, L.-X.; Zhou, Q.-L. Org. Lett. 2006, 8, 2567. (b) Jagt, R. B. C.; Toullec, P. Y.; Geerdink, D.; de Vries, J. G.; Feringa, B. L.; Minnaard, A. J. Angew. Chem., Int. Ed. 2006, 45, 2789. (c) Nakagawa, H.; Rech, J. C.; Sindelar, R. W.; Ellman, J. A. Org. Lett. 2007, 9, 5155. (d) Kurihara, K.; Yamamoto, Y.; Miyaura, N. Adv. Synth. Catal. 2009, 351, 260. (e) Hao, X.; Kuriyama, M.; Chen, Q.; Yamamoto, Y.; Yamada, K.; Tomioka, K. Org. Lett. 2009, 12, 4470.

(7) For examples with chiral bicyclo[3.3.0]octadienes, see : (a) Wang,
Z.-Q.; Feng, C.-G.; Xu, M.-H.; Lin, G.-Q. J. Am. Chem. Soc. 2007, 129, 5336.
(b) Yang, H.-Y.; Xu, M.-H. Chem. Commun. 2010, 46, 9223. (c) Wang, L.;
Wang, Z.-Q.; Xu, M.-H.; Lin, G.-Q. Synthesis 2010, 3263.

Journal of the American Chemical Society

(8) For examples with other chiral diene ligands, see: (a) Tokunaga, N.; Otomaru, Y.; Okamoto, K.; Ueyama, K.; Shintani, R.; Hayashi, T. *J. Am. Chem. Soc.* 2004, *126*, 13584. (b) Otomaru, Y.; Tokunaga, N.; Shintani, R.; Hayashi, T. Org. Lett. 2005, *7*, 307. (c) Okamoto, K.; Hayashi, T.; Rawal, V. H. Chem. Commun. 2009, 4815. (d) Shintani, R.; Takeda, M.; Tsuji, T.; Hayashi, T. J. Am. Chem. Soc. 2010, *132*, 13168. (e) Shao, C.; Yu, H.-J.; Wu, N.-Y.; Feng, C.-G.; Lin, G.-Q. Org. Lett. 2010, *12*, 3820. (f) Cao, Z.; Du, H. Org. Lett. 2010, *12*, 2602. (g) Shintani, R.; Takeda, M.; Soh, Y.-T.; Ito, T.; Hayashi, T. Org. Lett. 2011, *13*, 2977.

(9) Trincado, M.; Ellman, J. A. Angew. Chem., Int. Ed. 2008, 47, 5623. (10) In Ellman's preliminary investigation, chiral diphenyl-substituted bicyclo[3.3.0] octadiene was tested but offered the desired product in moderate yield and enantioselectivity; see ref 9.

(11) For the preparation of aliphatic *N*-tosylaldimines, see: Chemla, F.; Hebbe, V.; Normant, J.-F. *Synthesis* **2000**, 75.

(12) Hayashi, T.; Takahashi, M.; Takaya, Y.; Ogasawara, M. J. Am. Chem. Soc. 2002, 124, 5052.

(13) For selected recent examples on the synthesis of chiral 2-aryl pyrrolidines, see: (a) Dübon, P.; Farwick, A.; Helmchen, G. Synlett 2009, 1413. (b) Chang, M.; Li, W.; Hou, G.; Zhang, X. Adv. Synth. Catal. 2010, 352, 3121. (c) Leemans, E.; Mangelinckx, S.; De Kimpe, N. Chem. Commun. 2010, 46, 3122. (d) Reddy, L. R.; Das, S. G.; Liu, Y.; Prashad, M. J. Org. Chem. 2010, 75, 2236. (e) Reddy, L. R.; Prashad, M. Chem. Commun. 2010, 46, 222.

(14) For selected recent examples on the synthesis of chiral 2-aryl piperidines, see: (a) Amat, M.; Bassas, O.; Llor, N.; Cantó, M.; Pérez, M.; Molins, E.; Bosch, J. Chem.—Eur. J. 2006, 12, 7872. (b) Esquivias, J.; Arrayás, R. G.; Carretero, J. C. Angew. Chem., Int. Ed. 2007, 46, 9257. (c) Guizzetti, S.; Benaglia, M.; Cozzi, F.; Annunziata, R. Tetrahedron 2009, 65, 6354. (d) Lemire, A.; Charette, A. B. J. Org. Chem. 2010, 75, 2077.

(15) Such addition reactions were unsuccessful for the imine substrates with both *N*-diphenylphosphinoyl $[N-P(O)Ph_2]$ and *N-tert*butyloxycarbonyl (*N*-Boc) protecting groups. See Supporting Information for details.

(16) In recent advancements, 1.2 equiv of arylboronic acid is enough to obtain high reaction yield. See Supporting Information for details.